Latest Breaking News On - ஒருங்கிணைந்த ஆரோக்கியம் சிகிச்சையகம் - Page 1 : comparemela.com
New Job Listings In The Portland Area
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
New health scheme moves services closer to home
royalgazette.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from royalgazette.com Daily Mail and Mail on Sunday newspapers.
Doctors are seeing an increase in drug overdose deaths during the pandemic
Doctors are seeing an increase in drug overdose deaths during the pandemic By Kimberly Curth | January 28, 2021 at 4:38 PM CST - Updated January 28 at 5:51 PM
NEW ORLEANS (WVUE) - Shannon Prince lost her only child to an accidental overdose in 2019. Parker was only 25 and addicted to opioids.
“You don’t expect to lose your children before you go,” Prince said. ”He was a social genius. He had so many friends. He was so sweet and he and I were really, really close and I miss him so much.”
She lost him to the disease of addiction.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 .
Mateon Therapeutics, Inc.January 13, 2021 GMT
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against COVID-19.
“These interim results suggest that ARTIVeda is a well-tolerated and effective treatment for COVID-19 that produces a faster recovery time when compared to Standard of Care alone,” said Dr. Vuong Trieu, Chairman and CEO of Mateon.
MATEON ANNOUNCES POSITIVE INTERIM RESULTS FROM ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
Mateon Therapeutics, Inc.
ARTI-19 CLINICAL TRIAL EVALUATING COVID-19 THERAPEUTIC
AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVeda
TM against COVID-19.
“These interim results suggest that ARTIVeda is a well-tolerated and effective treatment for COVID-19 that produces a faster recovery time when compared to Standard of Care alone,” said Dr. Vuong Trieu, Chairman and CEO of Mateon.
ARTIVeda is Mateon’s lead Ayurvedic drug against COVID-19 in India and is being developed by Mateon in partnership with Windlas Biotech Private Limited (India). ARTI-19 India is being conducted by Windlas as part of Mateon’s global effort to deploy ARTIVeda across India, Afri
vimarsana © 2020. All Rights Reserved.